UPJOHN BROPIRIMINE SHOWS 51% COMPLETE RESPONSE RATE FOR BLADDER CARCINOMA
Executive Summary
UPJOHN BROPIRIMINE SHOWS 51% COMPLETE RESPONSE RATE FOR BLADDER CARCINOMA in a Phase II trial presented by Michael Sarosdy, MD, University of Texas, San Antonio, to the American Society of Clinical Oncology in Dallas May 17. A 3 g dally dose of the oral interferon inducer resulted in complete responses in 20 of 39 evaluable patients with bladder carcinoma in situ.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth